good cause, in a W2 employment position. Three refusals to participate in any W2 employment category would result in permanent ineligibility for that category. To assist families with one-time expenses, the State would provide Job Access Loans for employment support needs, e.g., car repair, uniforms, etc; and would extend child care to families earning up to 165 percent of poverty with graduated co-payments based on family income and the category of care used. Child care would only be provided to children under 13.

The State would limit participation to 24 months in any one W2 employment position and would limit lifetime eligibility for benefits to 60 months, with extensions on a case-by-case basis; the 60-month limit would apply to certain JOBS participants beginning July 1, 1996. The State would change AFDC cases headed by a non-legally responsible relative to a IV–E case; provide job search assistance and case management to non-custodial parents with a child support order; impose stricter sanctions for non-cooperation with child support; and permanently deny W2 employment after three Intentional Program Violations. Benefit overpayments will be recouped for intentional violations at a rate set by the State. Corrective payments would not be made for underpayments. Eligibility for Emergency Assistance for certain homeless persons would be limited to once in a 36-month period unless the homelessness was caused by domestic abuse, and the State would allow displacement of regular employees by W2 participants in certain cases: i.e., partial displacement (reduction in hours); impairment of existing contracts; infringement upon promotional opportunities; and filling of any established unfilled position.

The State would eliminate transitional Medicaid and expand Medicaid (i.e., the W2 Health Plan) to families with gross income up to 165 of FPL, who would then remain eligible until their income increases to 200 percent of FPL; and would incorporate a mandatory HMO enrollment or primary provider program for W2 participants. Participants would be required to pay a share of W2 Health Plan premiums according to a sliding scale, and the State would impose stricter Medicaid sanctions for non-cooperation with child support. The State would merge the Food Stamps E&T program with the W2 Work Program; modify the Food Stamps work program exemptions; eliminate the Food Stamps gross income test; require nutrition education for Food Stamps recipients; and cash out food stamps.

Date Received: 5/29/96.

Type: Combined AFDC/Medicaid.

Current Status: Pending.

Contact Person: Jean Sheil, (608) 266–0613.

Project Title: Wyoming—New Opportunities and New Responsibilities—Phase II (Amendments).

Description: Proposes expansion of demonstration provisions currently limited to a pilot site statewide and further amendments to the current demonstration to establish a 5-year lifetime limit on cash assistance for adults, beginning with time on AFDC from July 1, 1987 (with limited exemptions and extensions); pursue child support from the absent minor parent's parents; freeze benefits based on household size 10 months after initial qualification; replace existing earnings disregards for recipients (except no disregard will apply for recipients disqualified due to fraud, education time limits, illegal alien) with a maximum earned income disregard of $200 for recipients; expand pay-for-performance from AFDC–UP to the regular AFDC population, with limited exemptions, where failure to perform any item in the self-sufficiency plan would cause disqualification of the parent for AFDC, Food Stamps, and Medicaid; reduce the grant by $40 when a nonexempt child fails to meet the performance requirements; require able-bodied applicants and recipients to do job search for up to 16 weeks unless otherwise exempted; terminate the case when there is loss of contact with the client for 1 month after nonpayment for failure to meet the performance requirements; exclude the earned income and resources of a dependent child who is a full-time high school student; allow payment of the supplied shelter grant for households with a SSI recipient, unmarried minor parents, or recipients disqualified for other reasons (fraud, education time limits, illegal aliens); exclude one licensed vehicle with a fair market value of less than $12,000; increase the resource limit to $2,500 for those in compliance with, or exempted from, the performance requirements; and exclude veteran's service connected disability compensation if the annual income is less than the poverty level.

Date Received: 5/13/96.

Type: Combined AFDC/Medicaid.

Current Status: Pending.

Contact Person: Marianne Lee, (307) 777–6849.

III. Listing of Approved Proposals Since August 1, 1995

Project Title: California—Work Pays Demonstration Project (Amendment).
Contact Person: Bruce Wagstaff, (916) 657–2367.

Project Title: Hawaii—Pursuit Of New Opportunities (PONO).
Contact Person: Kristine Foster, (808) 586–5729.

Project Title: Indiana—Impacting Families Welfare Reform Demonstration—Amendments.
Contact Person: James H. Hmurovich, (317) 232–4704.

Project Title: Kansas—Actively Creating Tomorrow for Families Demonstration.
Contact Person: Diane Dystra, (913) 296–3028.

Project Title: Maryland—Family Investment Program (Amendments).
Contact Person: Kathy Cook, (410) 767–7055.

Project Title: Minnesota—Work First Program.
Contact Person: Gus Avenido, (612) 296–1884.

Project Title: Minnesota—AFDC Barrier Removal Project.
Contact Person: Ann Sessoms, (612) 296–0978.

IV. Requests for Copies of a Proposal

Requests for copies of an AFDC or combined AFDC/Medicaid proposal should be directed to the Administration for Children and Families (ACF) at the address listed above. Questions concerning the content of a proposal should be directed to the State contact listed for the proposal.

(Catalog of Federal Domestic Assistance Program, No. 93562; Assistance Payments—Research)

Dated: September 17, 1996.

Howard Rolston,

Director, Office of Planning, Research and Evaluation.

[FR Doc. 96–24207 Filed 9–19–96; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

[Docket No. 96N–0310]

Environmental Assessments and Findings of No Significant Impact

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it has reviewed environmental assessments (EA's) and issued findings

of no significant impact (FONSI's) relating to the 51 new drug applications (NDA's) or supplements listed in this document. FDA is publishing this notice because Federal regulations require public notice of the availability of environmental documents.

ADDRESSES: The EA's and FONSI's may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, or a copy may be requested by writing the Freedom of Information Staff (HFI–35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Nancy B. Sager, Center for Drug Evaluation and Research (HFD–357), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–5721.

SUPPLEMENTARY INFORMATION: Under the National Environmental Policy Act of 1969 (NEPA), Congress declared that it will be the continuing policy of the Federal Government to ''use all practicable means and measures, including financial and technical assistance, in a manner calculated to foster and promote the general welfare, to create and maintain conditions under which man and nature can exist in productive harmony, and fulfill the social, economic and other requirements of present and future generations of Americans.'' (See 42 U.S.C. 4331(a).) NEPA requires all Federal agencies to include in every proposal for major Federal actions significantly affecting the quality of the human environment, a detailed statement assessing the environmental impact of, and alternatives to, the proposed action and to make available to the public such statements. (See 42 U.S.C. 4332, 40 CFR 1506.6, and 21 CFR 25.41(b).)

FDA implements NEPA through its regulations in part 25 (21 CFR part 25). Under those regulations, actions to approve NDA's and supplements to existing approvals ordinarily require the preparation of an EA. (See § 25.22(a)(8) and (a)(14).)

FDA approved 51 NDA's or supplemental NDA's for the products listed in the following table:

Drug	NDA
Versed (midazolam) Injection	18–654/S–026
Zantac (ranitidine hydrochloride) Tablets	18–703/S–051
Zantac (ranitidine hydrochloride) Syrup	19–675/S–016
Prilosec (omeprazole) Capsules	19–810/S–019
Zyrtec (cetirizine hydrochloride) Tablets	19–835
Zofran (ondansetron hydrochloride) Injection	20–007/S–005 and S–018
Paxil (paroxetine hydrochloride) Tablets	20–031/S–007 and S–009
Thioplex (thiotepa) Injection	20–058
Habitrol (nicotine transdermal)	20–076/S–006
Zantac (ranitidine hydrochloride) Capsules	20–095
Flonase (fluticasone propionate) Nasal Spray	20–121
Imitrex (sumatriptan succinate) Tablets	20–132
Effexor (venlafaxine hydrochloride) Tablets	20–151
Serzone (nefazodone hydrochloride) Tablets	20–152
Perindopril Erbumine Tablets	20–184
Prozac (fluoxetine hydrochloride) Capsules/Oral Solution	20–187
Ultravist (iopromide) Injection	20–220
Tagamet (cimetidine) Tablets	20–238
Renormax (spirapril hydrochloride) Tablets	20–240
Lamictal (lamotrigine) Tablets	20–241
Luvox (fluvoxamine maleate) Tablets	20–243
Neurolite (bicisate dihydrochloride) Injection	20–256
Risperdal (risperidone) Caplets	20–272
Ultram (tramadol hydrochloride) Tablets	20–281
Coreg (carvedilol) Tablets	20–297
Trasylol (aprotinin) Injection	20–304
Univasc (moexipril hydrochloride) Tablets	20–312
Pepcid AC (famotidine) Tablets	20–325
Primacor (milrinone lactate) Injection	20–343
Sular (nisoldipine) ER Tablets	20–356
Glucophage (metformin hydrochloride) Tablets	20–357
Famvir (famiciclovir) Tablets	20–363
Cozaar (lorsartan potassium) Tablets	20–386
Hyzaar (losartan K/hydroclorothiazide) Tablets	20–387
Navelbine (vinorelbine tartrate) Injection	20–388
Atrovent (ipratropium bromide) Nasal Spray	20–393
Atrovent (ipratropium bromide) Nasal Spray	20–394
Prevacid (lansoprazole) Capsules	20–406
Trusopt (dorzolamide HCl) Ophthalmic Solution	20–408
Photofrin (porfirmer sodium) Injection	20–451
Precose (acabrose) Tablets	20–482
Casodex (bicalutamide) Tablets	20–498
Zantac (ranitidine hydrochloride) Tablets	20–520
Fosamax (alendronate sodium) Tablets	20–560
Dynabac (dirithromycin) Tablets	50–678
Cedax (ceftibuten) Capsules	50–685
Cedax (ceftibuten) Capsules	50–686
Neoral (cyclosporine microemulsion) Gel	50–715
Neoral (cyclosporine microemulsion) Oral	50–716

As part of its review of each of the NDA's and supplements listed in this table, FDA reviewed an EA. In each instance, FDA found that the approval of the NDA or supplement will not significantly affect the human environment. In accordance with the Council on Environmental Quality regulations in 40 CFR 1501.4(e) and FDA regulations in § 25.32, FDA prepared a FONSI for each NDA and supplement. This notice announces that the EA's and FONSI's for these human drug products may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. For a fee, copies of these EA's and FONSI's may

be obtained by writing the Freedom of Information Staff (address above). The request should identify by the NDA number the EA's and FONSI's requested. Separate requests should be submitted for each NDA. For additional information regarding the submission of freedom of information requests call 301–443–6310.

Dated: September 13, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–24149 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96G–0324]

Roquette America, Inc., and American Maize-Products Co.; Filing of a Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Roquette America, Inc., and American Maize-Products Co. have filed a petition (GRASP 6G0421) proposing to affirm that beta-cyclodextrin is generally recognized as safe (GRAS) as a flavor protectant in human food.

DATES: Written comments by December 4, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mitchell A. Cheeseman, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3083.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (secs. 201(s) and 409(b)(5) (21 U.S.C. 321(s) and 348(b)(5)), and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that Roquette America, Inc., and American Maize-Products Co., c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001, have filed a petition (GRASP 6G0421) proposing to affirm that beta-cyclodextrin is GRAS as a flavor protectant in human food.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in §§ 170.30 (21 CFR 170.30) and 170.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Interested persons may, on or before December 4, 1996, review the petition and file comments with the Dockets Management Branch (address above). Two copies of any comments should be filed and should be identified with the docket number found in brackets in the heading of this document. Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. In addition, consistent with the regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency encourages public participation by review of and comment on the environmental assessment submitted with the petition that is the subject of this notice. A copy of the petition (including the environmental assessment) and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 14, 1996.

Eugene C. Coleman,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–24148 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee Meeting; Postponement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Antiviral Drugs Advisory Committee scheduled for September 26 and 27, 1996. The meeting was announced by a notice in the Federal Register of September 4, 1996 (61 FR 46652). This meeting is being postponed to allow time to incorporate the results of additional study information which have recently become available for the new drug application 20–705, delavirdine (Rescriptor®, Pharmacia and Upjohn Co.) for use in the treatment of human immunodeficiency virus (HIV) infection. The meeting will be rescheduled at a later date and will be announced in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Rhonda W. Stover, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455; or call the FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Antiviral Drugs Advisory Committee, code 12531.

Dated: September 13, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–24147 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

Submission for OMB Review; Comment Request; Agricultural Health Study—A Prospective Cohort Study of Cancer and Other Diseases Among Men and Women in Agriculture

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on June 13, 1996 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented after 10/1/95, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: Title: Agricultural Health Study—A Prospective Cohort Study of Cancer and Other Diseases Among Men and Women in Agriculture. Type of Information Collection Request: Revision (0925–0406, expiration 8/13/96). Need and Use of Information Collection: The Agricultural Health Study is in its third year of data collection on a prospective cohort of 75,000 farmers, their spouses, and commercial applicators of pesticides from Iowa and North